Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALLK

ALLK - Allakos Inc Stock Price, Fair Value and News

1.65USD+0.17 (+11.49%)Delayed as of 01 Mar 2024, 03:04 pm ET
Watchlist

Market Summary

USD1.65+0.17
Delayedas of 01 Mar 2024, 03:04 pm
11.49%

ALLK Alerts

  • CITADEL ADVISORS LLC reported owning 3.4% of ALLK [2024-02-14]

ALLK Stock Price

View Fullscreen

ALLK RSI Chart

ALLK Valuation

Market Cap

129.5M

Price/Earnings (Trailing)

-0.78

EV/EBITDA

-0.47

Price/Free Cashflow

-0.93

MarketCap/EBT

-1.29

ALLK Price/Sales (Trailing)

ALLK Profitability

Return on Equity

-75.16%

Return on Assets

-58.6%

Free Cashflow Yield

-108.07%

ALLK Fundamentals

ALLK Earnings

Earnings (TTM)

-166.1M

Earnings Growth (Yr)

-47.96%

Earnings Growth (Qtr)

-29.91%

Breaking Down ALLK Revenue

52 Week Range

1.526.74
(Low)(High)

Last 7 days

-6.7%

Last 30 days

-58.2%

Last 90 days

-33.9%

Trailing 12 Months

-80.6%

How does ALLK drawdown profile look like?

ALLK Financial Health

Current Ratio

9.31

ALLK Investor Care

Shares Dilution (1Y)

2.67%

Diluted EPS (TTM)

-1.49

Tracking the Latest Insider Buys and Sells of Allakos Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 04, 2023
alexander robert
sold (taxes)
-61,882
2.5
-24,753
chief executive officer
Dec 04, 2023
radford harlan baird
sold (taxes)
-20,950
2.5
-8,380
chief financial officer
Dec 04, 2023
paterson craig a.
sold (taxes)
-17,480
2.5
-6,992
chief medical officer
Dec 04, 2023
tomasi adam
sold (taxes)
-40,135
2.5
-16,054
president
Sep 05, 2023
tomasi adam
sold (taxes)
-54,839
3.01
-18,219
president
Sep 05, 2023
paterson craig a.
sold (taxes)
-23,884
3.01
-7,935
chief medical officer
Sep 05, 2023
alexander robert
sold (taxes)
-84,569
3.01
-28,096
chief executive officer
Sep 05, 2023
radford harlan baird
sold (taxes)
-28,628
3.01
-9,511
chief financial officer
Aug 16, 2023
alta partners management viii, llc
acquired
-
-
1,463,380
-
Aug 16, 2023
alta partners management viii, llc
sold
-
-
-6,448,050
-

1–10 of 50

Which funds bought or sold ALLK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
14,898
90,210
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
24.89
7,227,000
21,624,000
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-57.03
-33,433
35,591
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-77.68
-679,000
249,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
693
693
-%
Feb 15, 2024
Virtus ETF Advisers LLC
added
45.67
34,435
80,237
0.05%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-49.82
-273,383
416,050
-%
Feb 14, 2024
JANUS HENDERSON GROUP PLC
sold off
-100
-76,361
-
-%
Feb 14, 2024
CAXTON CORP
reduced
-49.91
-44,521
67,457
0.36%
Feb 14, 2024
CITADEL ADVISORS LLC
reduced
-21.75
-555,132
8,858,640
-%

1–10 of 46

Are Funds Buying or Selling ALLK?

Are funds buying ALLK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALLK
No. of Funds

Unveiling Allakos Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
2.87%
2,510,736
SC 13G/A
Feb 14, 2024
logos global management lp
3.3%
2,900,000
SC 13G/A
Feb 14, 2024
citadel advisors llc
3.4%
6
SC 13G/A
Feb 12, 2024
price t rowe associates inc /md/
9.1%
7,920,708
SC 13G
Feb 12, 2024
price t rowe associates inc /md/
0.7%
638,102
SC 13G/A
Feb 02, 2024
rivervest venture fund iii, l.p.
0.0%
0
SC 13D/A
Jan 29, 2024
blackrock inc.
5.8%
5,116,088
SC 13G
Jan 26, 2024
deep track capital, lp
5.72%
5e+06
SC 13G
Jan 26, 2024
deep track capital, lp
2.87%
2,510,736
SC 13G/A
Jan 18, 2024
biotechnology value fund l p
5.2%
4,558,983
SC 13G/A

Recent SEC filings of Allakos Inc

View All Filings
Date Filed Form Type Document
Feb 26, 2024
8-K
Current Report
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 16, 2024
3
Insider Trading
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
8-K
Current Report

Peers (Alternatives to Allakos Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
35.3B
6.8B
-16.59% -47.80%
-7.48
5.15
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.0B
1.8B
-23.99% -31.71%
-43.22
10.41
76.23% 61.08%
16.3B
2.4B
-4.89% -18.90%
97.14
6.73
15.42% 18.43%
13.1B
3.7B
-7.62% -26.87%
21.93
3.55
8.87% 75.42%
MID-CAP
7.5B
396.6M
-2.06% 34.31%
-14.14
18.84
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.63
60.35
54.84% -25.61%
4.0B
240.7M
-19.08% -10.99%
-13.4
16.52
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.12
14.25
440.80% -27.84%
3.8B
726.4M
-12.60% 32.37%
-62.48
5.27
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-3.38% -9.50%
26.46
4.74
85.90% -14.05%
687.2M
983.7M
-9.17% -57.89%
-1.26
0.7
-50.36% 17.16%
201.6M
4.9M
-14.18% -58.18%
-1.22
41.23
-57.57% 50.48%
135.5M
881.7K
289.54% 381.25%
-2.86
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Allakos Inc News

Latest updates
InvestorsObserver27 Feb 202406:06 pm
Seeking Alpha17 Jan 202408:00 am
Seeking Alpha16 Jan 202408:00 am
InvestorPlace16 Jan 202408:00 am
Yahoo Finance16 Jan 202408:00 am

Allakos Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-11.2%283319350386419307346535621655684720441474500517535170185191206
  Current Assets-13.2%218252283309339222258452531576629669425458484500520154169182197
    Cash Equivalents4.7%71.0067.0094.0087.0020582.0036.0015327420417020710415413641.0030936.0031.0034.0052.00
  Net PPE-4.1%35.0036.0038.0039.0040.0041.0044.0043.0040.0025.0014.008.007.008.008.008.008.009.009.009.008.00
Liabilities-2.8%62.0064.0070.0076.0074.0084.0086.0089.0097.0084.0068.0065.0027.0027.0022.0021.0021.0018.0017.007.0010.00
  Current Liabilities-4.2%23.0024.0030.0030.0028.0037.0038.0040.0041.0034.0023.0022.0019.0020.0014.0013.0012.009.008.005.008.00
Shareholder's Equity-13.3%221255280310344223260445525571616654414447478496514152168184196
  Retained Earnings-4.5%-1,055-1,010-975-932-889-858-809-612-518-455-398-342-298-256-217-189-164-143-124-104-89.58
  Additional Paid-In Capital0.9%1,2771,2651,2561,2431,2341,0821,0701,0581,0431,0271,014997712703693685679295292288286
Shares Outstanding0.8%87.0087.0087.0085.0058.0055.0055.0055.0054.0053.0053.0049.00---------
Float------121---3,237---2,156---959---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations9.6%-29,479-32,594-30,139-46,786-26,128-32,770-174,287-65,377-46,435-49,782-46,259-34,415-35,823-25,072-18,614-19,111-16,199-14,423-13,279-12,649-8,352
  Share Based Compensation7.3%10,5349,82110,6659,27310,73211,76111,39214,59512,49611,39712,35410,2067,9897,7627,4895,8653,9603,1052,8342,539979
Cashflow From Investing415.4%31,5476,12135,318-71,4777,68778,05957,412-57,085113,08682,9494,288-137,525-15,29841,320115,400-249,862-91,50719,27810,120-5,330-99,321
Cashflow From Financing-1,070-1,458190141,27966.003478643,8138004,783274,8141,5261,7087898.00380,0541389634.00140,013

ALLK Income Statement

2023-09-30
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses    
Research and development$ 36,749$ 18,438$ 97,107$ 229,693
General and administrative11,46113,00733,96646,520
Total operating expenses48,21031,445131,073276,213
Loss from operations(48,210)(31,445)(131,073)(276,213)
Interest income2,5907117,965898
Other expense, net(6)(103)(42)(1,648)
Net loss(45,626)(30,837)(123,150)(276,963)
Unrealized gain on investments8719621289
Comprehensive loss$ (45,539)$ (30,641)$ (122,938)$ (276,874)
Net loss per common share:    
Net loss per common share, basic$ (0.52)$ (0.53)$ (1.42)$ (4.95)
Net loss per common share, diluted$ (0.52)$ (0.53)$ (1.42)$ (4.95)
Weighted-average number of common shares outstanding:    
Weighted-average shares of common stock outstanding, basic87,11558,16986,53955,905
Weighted-average shares of common stock outstanding, diluted87,11558,16986,53955,905

ALLK Balance Sheet

2023-09-30
BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 70,519$ 87,217
Investments123,389192,569
Prepaid expenses and other current assets24,37129,057
Total current assets218,279308,843
Property and equipment, net34,96539,144
Operating lease right-of-use assets24,16730,225
Other long-term assets6,0848,208
Total assets283,495386,420
Current liabilities:  
Accounts payable9154,832
Accrued expenses and other current liabilities22,53525,206
Total current liabilities23,45030,038
Operating lease liabilities, net of current portion39,00245,949
Total liabilities62,45275,987
Contingencies (Note 7) 
Stockholders’ equity:  
Preferred stock, $0.001 par value per share; 20,000 shares authorized as of September 30, 2023 and December 31, 2022; no shares issued and outstanding as of September 30, 2023 and December 31, 202200
Common stock, $0.001 par value per share; 200,000 shares authorized as of September 30, 2023 and December 31, 2022; 87,476 and 85,387 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively8785
Additional paid-in capital1,276,9541,243,408
Accumulated other comprehensive loss(72)(284)
Accumulated deficit(1,055,926)(932,776)
Total stockholders’ equity221,043310,433
Total liabilities and stockholders’ equity$ 283,495$ 386,420
ALLK
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.
 CEO
 WEBSITEwww.allakos.com
 EMPLOYEES123

Allakos Inc Frequently Asked Questions


What is the ticker symbol for Allakos Inc? What does ALLK stand for in stocks?

ALLK is the stock ticker symbol of Allakos Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allakos Inc (ALLK)?

As of Thu Feb 29 2024, market cap of Allakos Inc is 129.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLK stock?

You can check ALLK's fair value in chart for subscribers.

What is the fair value of ALLK stock?

You can check ALLK's fair value in chart for subscribers. The fair value of Allakos Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allakos Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALLK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allakos Inc a good stock to buy?

The fair value guage provides a quick view whether ALLK is over valued or under valued. Whether Allakos Inc is cheap or expensive depends on the assumptions which impact Allakos Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLK.